Search 

AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Our lead product, ARX-01, is currently being evaluated in Phase 3 studies for the treatment of moderate to severe acute pain in the hospital setting. ARX-01 is designed to enable patient control, remove impediments to ambulation, and improve patient satisfaction. By utilizing sublingual delivery of sufentanil NanoTabs(R) thorugh our proprietary handheld system, ARX-01 avoids the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. By delivering sufentanil through the oral transmucosal route, ARX-01 offers the potential to improve upon the typical side effect profile of morphine. 

We have three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office; and ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.

Acorda Therapeutics, Inc. is a biotechnology company whose mission is to develop and market therapies that restore neurological function and improve the lives of people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The Company's marketed products include AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. and ZANAFLEX CAPSULES® (tizanidine hydrochloride). AMPYRA® is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. ZANAFLEX CAPSULES® is a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

AlloCure is a Boston-based biotechnology company developing AC607, an allogeneic mesenchymal stem cell therapy for the treatment acute kidney injury (AKI) with potential applications in other grievous illnesses. 

Building on the success of a phase 1 clinical trial, AlloCure has initiated ACT-AKI, a randomized, multicenter, double-blind, placebo-controlled phase 2 trial in cardiac surgery subjects with post-operative AKI. Currently, there are no available treatment options for patients with AKI other than supportive care. AC607 represents the first application of a cell therapy to alter the course of this life threatening condition.

AriVan Research LLC (AVR) is a specialized consulting firm that works closely with biopharmaceutical companies, diagnostic companies, medical device manufacturers, and other clients to support business development, commercialization and R&D activities.  Our expertise involves conducting in-depth primary research with KOLs, clinical investigators, healthcare company personnel, payers, and other industry sources to address important business- and scientific-related questions and issues.  A thorough analysis of secondary and/or audit data is often completed as well.  From there, our highly-experienced group of MBAs, MDs & PharmDs analyzes the information to provide rational and insightful recommendations.  

Avanir Pharmaceuticals, Inc. is a biotechnology company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.  Our lead product, NUEDEXTA, is a dual sigma-1/NMDA receptor modulator and is the first and only FDA-approved treatment for pseudobulbar affect (PBA).  PBA is a condition affecting many patients with Alzheimer's / dementia, stroke, MS, Parkinson's, and other forms of neurological disease or injury and is characterized by uncontrolled episodes of crying or laughing.  

Avanir is commercializing NUEDEXTA in the United States through its specialty sales force calling primarily on neurology and psychiatry clinics as well as nursing homes.  Recent commercial milestones include over 10,000 Rx's during the month of August 2012 (up 9% relative to the prior month), which equates to a gross NUEDEXTA sales run-rate of over $65 million per year.

Avanir has a pending MAA for NUEDEXTA with the European regulatory authorities and is also conducting clinical trials in additional indications such as agitation in dementia, neuropathic pain in multiple sclerosis, and other areas where dual sigma-1/NMDA receptor targeted therapies can address unmet needs.    

BioPharm Insight is the premier online business intelligence tool used by most Business Development and Strategy teams- to help them more efficiently target, track and identify opportunitues and the competitive landscape. The best way to understand how you can leverage you personalized radar of real-time and proprietary intel, detailed deal comps, and forecasts, is to see an online demo of the tool. Please suggest the best time and place for us to show you exactly how we can help or visit us at www.biopharminsight.com